Aura Biosciences Overview
- Year Founded
-
2007
- Status
-
Public
- Employees
-
89
- Stock Symbol
-
AURA
- Share Price
-
$8.10
- (As of Thursday Closing)
Aura Biosciences General Information
Description
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its lead candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
Contact Information
Website
www.aurabiosciences.comCorporate Office
- 85 Bolton Street
- Cambridge, MA 02140
- United States
Corporate Office
- 85 Bolton Street
- Cambridge, MA 02140
- United States
Aura Biosciences Stock Performance
As of 23-Jan-2025, Aura Biosciences’s stock price is $8.10. Its current market cap is $405M with 50M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $8.10 | $7.93 | $6.63 - $12.38 | $405M | 50M | 182K | -$1.73 |
Aura Biosciences Financials Summary
As of 30-Sep-2024, Aura Biosciences has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 273,608 | 307,576 | 298,469 | 630,590 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (91,737) | (83,559) | (59,427) | (34,433) |
| Net Income | (83,216) | (76,408) | (58,763) | (35,251) |
| Total Assets | 205,340 | 255,075 | 223,935 | 160,030 |
| Total Debt | 19,084 | 19,557 | 20,858 | 975 |
Aura Biosciences Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Aura Biosciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Aura Biosciences Comparisons
Industry
Financing
Details
Aura Biosciences Competitors (54)
One of Aura Biosciences’s 54 competitors is ImmunityBio, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| ImmunityBio | Formerly VC-backed | San Diego, CA | ||||
| Amgen | Formerly PE-Backed | Thousand Oaks, CA | ||||
| Sorrento Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Ember Therapeutics | Formerly VC-backed | New York, NY | ||||
| NexImmune | Formerly VC-backed | Gaithersburg, MD |
Aura Biosciences Patents
Aura Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20220152218-A1 | Human papillomavirus nanoparticle formulations | Pending | 26-Mar-2019 | ||
| EP-3946256-A1 | Human papillomavirus nanoparticle formulations | Active | 26-Mar-2019 | ||
| AU-2020248407-A1 | Human papillomavirus nanoparticle formulations | Pending | 26-Mar-2019 | ||
| CA-3134820-A1 | Human papillomavirus nanoparticle formulations | Pending | 26-Mar-2019 | ||
| EP-3946256-B1 | Virus-like particle formulations | Active | 26-Mar-2019 | A61K47/6901 |
Aura Biosciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Aura Biosciences ESG
Risk Overview
Risk Rating
Updated June, 13, 2023
27.4 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,104
Rank
Percentile
Pharmaceuticals
Industry
of 851
Rank
Percentile
Biotechnology
Subindustry
of 367
Rank
Percentile
Aura Biosciences FAQs
-
When was Aura Biosciences founded?
Aura Biosciences was founded in 2007.
-
Where is Aura Biosciences headquartered?
Aura Biosciences is headquartered in Cambridge, MA.
-
What is the size of Aura Biosciences?
Aura Biosciences has 89 total employees.
-
What industry is Aura Biosciences in?
Aura Biosciences’s primary industry is Drug Discovery.
-
Is Aura Biosciences a private or public company?
Aura Biosciences is a Public company.
-
What is Aura Biosciences’s stock symbol?
The ticker symbol for Aura Biosciences is AURA.
-
What is the current stock price of Aura Biosciences?
As of 23-Jan-2025 the stock price of Aura Biosciences is $8.10.
-
What is the current market cap of Aura Biosciences?
The current market capitalization of Aura Biosciences is $405M.
-
Who are Aura Biosciences’s competitors?
ImmunityBio, Amgen, Sorrento Therapeutics, Ember Therapeutics, and NexImmune are some of the 54 competitors of Aura Biosciences.
-
What is Aura Biosciences’s annual earnings per share (EPS)?
Aura Biosciences’s EPS for 12 months was -$1.73.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
